Nary a whisper of complaint would probably be heard from testosterone- infused males or Hollywood starlets (looking “to leave an impression” on some producers) about breast implant maker Mentor Corp.’s (MNT) executive pay practices.
CEO Joshua H. Levine earned an impressive $4.1 million in fiscal 2007 ended March 31, 2007, consisting of salary, cash bonuses, and stock and option awards of $500,000, $950,000, and $2.6 million, respectively.
Aesthetics of breast augmentation aside, the compensation package awarded to Levine illustrates—once again—two problems with executive pay practices:
(i) linking pay to performance is often undermined when Boards set benchmarks that are too subjective and weaken the link between CEO pay and corporate performance; (ii) an imbalance still exists between company stock performance and CEO pay.
For fiscal year 2007, the Compensation Committee at Mentor adopted a performance-based annual incentive bonus plan [“AIB”], which provided the Committee with the flexibility to design a cash-based incentive compensation program to motivate and reward performance for the year for its executive officers.
The benchmark used to determine minimum, target and maximum levels was founded upon Mentor’s achievement of specified results with respect to corporate operating income, or COI, for that fiscal year. The 10Q Detective noted, however that the Committee was granted the oversight “to modify” those bonus target levels:
In making the determination of minimum, target and maximum levels, the Committee retains wide discretion to interpret the terms of the AIB plan and to interpret and determine whether COI objectives or an individual’s performance objectives have been met in any particular fiscal year. The Committee also retains the right to exclude extraordinary charges or other special circumstances in determining whether our COI objectives were met during any particular fiscal year.
In addition, the target level with respect to COI has been based on confidential internal performance goals. In other words, the Committee does not have to clarify what they consider best practices to outside shareholders!
Fiscal 2007 was a notable roller coaster of a ride for common stockholders. , Following the November 17, 2006, announcement that the FDA approved for sale the Company’s MemoryGel silicone gel-filled breast implants, the share price peaked on November 21, at an intra-day high of $53.95, up almost 23% year-to-date. This news was material, for implants account for 87% of product sales.
On April 20, 2007, however, shares fell 17% to $40 per share on word from the medical products company that it would report lower-than expected fiscal year 2007 and 2008 sales and operating income.
In fiscal 2007, net sales increased 13% to $302.0 million from $268.3 million in the prior year. Net sales of breast implant products for plastic and reconstructive surgery increased 13% to $262.6 million from $233.2 million in the prior year. However, the Company saw (only) overall growth in unit sales of breast implant products of approximately 6 percent.
Corporate operating income for the 12-months ended March 31, 2007, fell 5% to $65.6 million, due to higher SG&A, R&D, and asset impairment and restructuring charges.
Nonetheless, the Board saw fit to pay CEO Levine a cash performance bonus of $500,000—or 100% of target levels attainable in fiscal 2007. Again, as COI target bonuses were based on confidential internal performance goals—and not reported operating income—the Board had free reign to unlink pay to performance!
The Board may also approve cash bonuses outside of the AIB plan. For example, the Committee may approve bonus awards in connection with an executive officer’s efforts and accomplishments with respect “to strategic initiatives and milestones, and such bonus awards may overlap with or be in addition to bonus awards under the AIB plan.”
In fiscal year 2007, the Committee approved two special cash bonus awards to Mr. Levine in the aggregate of $450,000: a payment of $200,000 to compensate him “for his contributions to the sale of a urology division” and $250,000 for “his leadership in multi-year efforts to obtain FDA approval of the silicone gel-filled breast implants.”
Are we missing something—or do not the foregoing fall under expected JOB DESCRIPTION?
The Board rewards Named Executive Officers with annual grants of stock options, shares of restricted stock, and Performance Stock Units [PSUs], the size of which took into consideration a number of performance metrics with respect to annual rewards, including cash flow, revenue and share-net. The objective was to align employee interests with those of other stockholders.
In fiscal 2007, cash flow from operations fell 30% to $68.9 million (from the prior year) and % Return on Assets and % Return on Equity fell 10 basis points and 670 basis points to 9.2% and 17.4%, respectively.
Irrespective of these non-performing metrics, the Board still saw fit to reward Mr. Levine with $1.93 million and $702,318 in stock grants and stock options, respectively.
Investors initially bid up the share price of Mentor on expectations that the Company’s ability to sell (higher-margin) silicone-gel implants in the U.S. for women who wanted breast augmentation would yield healthy revenue and share-net gains for Mentor. As that promise proved premature, the stock fell.
Despite the hasty retreat in market valuation, CEO Levine is still sitting in the catbird seat seat. At fiscal year-end March 31, 2007, he held exercisable options for 171,250 shares at exercise prices ranging from $19.01 to $37.70 per share. In addition, in fiscal 2007, Mr. Levine exercised 100,000 shares with an unrealized gain of $3.32 million (not reported in 2007 compensation).
In its 2007 Proxy Statement, the Board reiterated that the ultimate objective of its compensation program was to improve shareholder value. In the last year, the stock lost $515.0 million in value, and currently has a market capitalization of $1.63 billion. Looks like the Board failed at that objective, too.
The 10Q Detective believes that Mentor (which formerly sold penile implants!) has an attractive, aesthetic implant business model, especially if it can execute on selling more of the silicone implants. The silicone-gel implants, which supposedly feel more like natural tissue, sell for about $600 (twice as much as the saline-filled aesthetic devices). Unfortunately, management has yet to demonstrate its ability to reign in costs and sell in a competitive market.
Author David J. Phillips does not hold a financial interest in Mentor Corp. The 10Q Detective has a Full Disclosure Policy.